Pharma Marketing Network

This article summarizes the results of the KOL Name Change Survey and discusses how to change the underlying process by which pharma companies choose KOLs.

The FDA approved a total of 41 new molecular entities (NMEs) and biologics (BLAs) in 201 4but sent out only a meager 10 advertising enforcement letters in 2014, the fewest ever.

Here's John Mack's list of 2015 resolutions for pharmaceutical marketers. Hopefully, at least one of these will be kept, although no one is making any promises.

In this article, Pharmaguy presents the best images from Pharma Marketing Blog, which cover topics of importance in 2014: DTC and drug promotion spending, drug risks and adverse events, drug industry reputation, FDA and social media regulatory guidelines, mobile apps, and drug development costs.

Welcome to Volume 14, Issue #1 (JANUARY 2015) of Pharma Marketing News.

My #1 New Year's Resolution is the same every year:  Stop telling pharmaceutical marketers what to do all the time. Unfortunately, I have never kept that...

The ad shown on the left is the subject of an FDA/OPDP "untitled letter" (definition), which took aim at a Sunovion professional print ad...

These are my favorite images and posts that appeared in Pharma Marketing Blog in 2014 (see embedded slide deck below - you can also...

FDA approved Amgen's Blincyto (blinatumomab) on December 3, 2014, as a second-line treatment for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, which affects around...

Pfizer marketers have done it again! First it was an all-female Viagra ad campaign for the treatment of ED (erectile dysfunction; read "Oh Yeah,...